HLB Life Science Balance Sheet Health
Financial Health criteria checks 3/6
HLB Life Science has a total shareholder equity of ₩433.6B and total debt of ₩163.5B, which brings its debt-to-equity ratio to 37.7%. Its total assets and total liabilities are ₩612.6B and ₩179.0B respectively.
Key information
37.7%
Debt to equity ratio
₩163.55b
Debt
| Interest coverage ratio | n/a |
| Cash | ₩113.62b |
| Equity | ₩433.60b |
| Total liabilities | ₩178.98b |
| Total assets | ₩612.58b |
Recent financial health updates
HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?
Apr 12
Is HLB Life Science (KOSDAQ:067630) A Risky Investment?
Jan 10Recent updates
HLB Life Science Co., Ltd.'s (KOSDAQ:067630) Popularity With Investors Under Threat As Stock Sinks 26%
Oct 24What HLB Life Science Co., Ltd.'s (KOSDAQ:067630) P/S Is Not Telling You
Aug 30HLB Life Science (KOSDAQ:067630) Shareholders Should Be Cautious Despite Solid Earnings
May 21HLB Life Science Co., Ltd.'s (KOSDAQ:067630) 25% Share Price Surge Not Quite Adding Up
Mar 15HLB Life Science (KOSDAQ:067630) Has Debt But No Earnings; Should You Worry?
Apr 12Did You Participate In Any Of HLB Life Science's (KOSDAQ:067630) Incredible 442% Return?
Feb 14Is HLB Life Science (KOSDAQ:067630) A Risky Investment?
Jan 10We're Not So Sure You Should Rely on HLB Life Science's (KOSDAQ:067630) Statutory Earnings
Dec 06Financial Position Analysis
Short Term Liabilities: A067630's short term assets (₩137.1B) exceed its short term liabilities (₩100.8B).
Long Term Liabilities: A067630's short term assets (₩137.1B) exceed its long term liabilities (₩78.2B).
Debt to Equity History and Analysis
Debt Level: A067630's net debt to equity ratio (11.5%) is considered satisfactory.
Reducing Debt: A067630's debt to equity ratio has increased from 2.6% to 37.7% over the past 5 years.
Debt Coverage: A067630's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if A067630's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 08:56 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HLB Life Science Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|